Follow
Richard Goldberg MD
Richard Goldberg MD
Professor emeritus, West Virginia University
Verified email at hsc.wvu.edu
Title
Cited by
Cited by
Year
PD-1 blockade in tumors with mismatch-repair deficiency
DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ...
New England Journal of Medicine 372 (26), 2509-2520, 2015
95382015
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
60622017
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ...
The Lancet 381 (9863), 303-312, 2013
30772013
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg, DJ Sargent, RF Morton, CS Fuchs, RK Ramanathan, ...
Journal of Clinical Oncology 22 (1), 23-30, 2004
29832004
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic, DJ Sargent, MJ Moore, SN Thibodeau, AJ French, ...
New England Journal of Medicine 349 (3), 247-257, 2003
27002003
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
J Tepper, MJ Krasna, D Niedzwiecki, D Hollis, CE Reed, R Goldberg, ...
Journal of clinical oncology: official journal of the American Society of …, 2008
15452008
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey, D Sargent, RM Goldberg, HJ Schmoll
Journal of Clinical Oncology 22 (7), 1209-1214, 2004
13432004
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
S Gill, CL Loprinzi, DJ Sargent, SD Thomé, SR Alberts, DG Haller, ...
Journal of clinical oncology 22 (10), 1797-1806, 2004
13232004
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients
DJ Sargent, RM Goldberg, SD Jacobson, JS Macdonald, R Labianca, ...
New England Journal of Medicine 345 (15), 1091-1097, 2001
11722001
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ...
Journal of Clinical Oncology 28 (22), 3617, 2010
9882010
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors
NM Lindor, LJ Burgart, O Leontovich, RM Goldberg, JM Cunningham, ...
Journal of clinical oncology 20 (4), 1043-1048, 2002
9762002
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...
Jama 317 (23), 2392-2401, 2017
8312017
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ...
Journal of Clinical Oncology 23 (34), 8664-8670, 2005
7822005
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials
D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ...
Journal of Clinical Oncology 27 (6), 872, 2009
7302009
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08
CJ Allegra, G Yothers, MJ O'Connell, S Sharif, NJ Petrelli, LH Colangelo, ...
Journal of Clinical Oncology 29 (1), 11, 2011
7262011
Platinum neurotoxicity pharmacogenetics
SR McWhinney, RM Goldberg, HL McLeod
Molecular cancer therapeutics 8 (1), 10-16, 2009
6992009
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X
NM Lindor, K Rabe, GM Petersen, R Haile, G Casey, J Baron, S Gallinger, ...
Jama 293 (16), 1979-1985, 2005
6802005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study
SR Alberts, WL Horvath, WC Sternfeld, RM Goldberg, MR Mahoney, ...
J Clin Oncol 23 (36), 9243-9249, 2005
6632005
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841
J Franko, Q Shi, CD Goldman, BA Pockaj, GD Nelson, RM Goldberg, ...
Journal of Clinical Oncology 30 (3), 263, 2012
6262012
Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer
R Pearlman, WL Frankel, B Swanson, W Zhao, A Yilmaz, K Miller, ...
JAMA oncology 3 (4), 464-471, 2017
5972017
The system can't perform the operation now. Try again later.
Articles 1–20